Athena Global Investors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 19.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,111 shares of the company’s stock after selling 2,461 shares during the period. Eli Lilly and accounts for 2.6% of Athena Global Investors LLC’s portfolio, making the stock its 19th largest position. Athena Global Investors LLC’s holdings in Eli Lilly and were worth $850,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently modified their holdings of the company. Heritage Trust Co acquired a new stake in Eli Lilly and during the 1st quarter worth $135,000. Penserra Capital Management LLC grew its holdings in Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after acquiring an additional 176 shares during the period. Crestwood Advisors Group LLC acquired a new stake in Eli Lilly and during the 1st quarter worth $179,000. Sandy Spring Bank grew its holdings in Eli Lilly and by 51.8% during the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after acquiring an additional 750 shares during the period. Finally, Coldstream Capital Management Inc. acquired a new stake in Eli Lilly and during the 1st quarter worth $200,000. 75.77% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Athena Global Investors LLC Lowers Position in Eli Lilly and Company (LLY)” was originally reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/09/10/athena-global-investors-llc-lowers-position-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company (NYSE:LLY) traded up 1.69% during midday trading on Friday, reaching $82.92. 3,961,293 shares of the company traded hands. The company has a 50 day moving average of $80.99 and a 200-day moving average of $82.04. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The stock has a market capitalization of $87.48 billion, a P/E ratio of 35.88 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the company posted $0.86 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
A number of analysts have commented on the stock. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 target price on shares of Eli Lilly and in a report on Sunday, May 21st. TheStreet lowered shares of Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. BMO Capital Markets reaffirmed an “underperform” rating and set a $73.00 target price on shares of Eli Lilly and in a report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $88.07.
In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total transaction of $17,730,300.00. Following the completion of the sale, the insider now owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Insiders sold 826,900 shares of company stock valued at $68,610,132 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.